Tang yan hd sex photo in Best international sex dating free signup sites

Posted by / 22-Jul-2018 04:45

Tang yan hd sex photo in

At the time of submission, you will be asked to confirm that you will pay the relatively inexpensive open access fee of 0.00 for articles up to 5 printed pages,

At the time of submission, you will be asked to confirm that you will pay the relatively inexpensive open access fee of $600.00 for articles up to 5 printed pages, $1,000.00 for 5-12 printed pages and $50.00 for each additional printed page over 12 pages. There is a $50.00 administration fee that will be added to the Open Access fee. D., 549Paz-y-Miño, C., 395Paz-y-Miño, N., 395Perbellini, L., 409Peters, W. M., 349Peyruchaud, O., 173 (357*)Piacenza, F., 409Pierpaoli, S., 409Piersiak, T., 419Podzimek, T., 163Poučková, P., 163Prasanna, R., 461Radpour, R., 57Raibowol, K., 95Ray, A., 269Reddanna, P., 243Reimann, K., 343Ren, Y., 1Rha, S. In addition, submissions that investigate the potential role of herbal/botanical medicines in preclinical and clinical cancer therapy are welcomed; however, it will be important to document that these medicines are of high quality, with confirmation of consistency. N., 243, 481Sasaki, A., 509Sawai, K., 541Scharovsky, O. K., 293Vinothini, G., 193von Deimling, A., 95, 469Wang, A., 377Wang, C., 561Wang, H., 359Wang, H., 519Wang, J., 359Wang, J.-G., 377Wang, M.-W., 133Wang, Y., 401Wang, Z., 359Wen, W., 73Wessner, B., 83Wimberger, P., 343Wiritsch, M., 83Wojtowicz, M., 127Wolowiec, D., 127Wu, Y., 1Wurm, R., 469Xiao, C., 561Xing, L., 1Xu, C., 1Xu, J.-H., 377Xu, Y., 359Xue, M., 503Xue, X., 561Yamaguchi, A., 541Yamaoka, T., 337Yamochi, T., 153Yan, Z., 519Yang, J., 437Yang, Y., 1Yang, Y., 519Yildiz, R., 583Yoo, B. S., 257 Asawakarn, S., 301 Aurello, P., 405 Bae, K.-H., 601 Barkhout, M., 347 Bauer, S. In addition to original peer-reviewed articles, the journal also welcomes timely reviews and/or commentaries on topics that focus on preclinical, translational, and/or clinical cancer therapeutics This e-mail address is being protected from spambots. G., 601Schumacher, U., 387Scott, A., 229Seki, T., 575Sevinc, A., 583Seyedabadi, M., 221Shah, S., 95Shichijo, T., 153, 493Shimada, C., 529Shirai, T., 337Siffert, W., 343Singh, H., 41, 329Singh, M. M., 293Singh, V., 293Sinn, B., 469Škvor, J., 163Sokolchik, I., 269Song, J.-C., 259Song, Y.-S., 453Souček, J., 163Srinivasan, R., 549Srivastava, S., 329Steed, P., 229Stehlík, J., 163Sturlan, S., 83Su, Z., 73Sugiyama, T., 337Sun, X.-F., 133Suzuki, E., 529Suzuki, H., 409Suzuki, K., 95Szteblich, A., 127 Taib, N. All authors must also agree to the addition of new authors. Kim, University of Ulsan College of Medicine, Korea T. Kim, University of Ulsan College of Medicine, Korea N. A., 73Du, Shuangkuan, 391Duggal, S., 73El-Hamamsy, M., 523Ellidokuz, H., 41Elwakil, H., 523Fan, Hua, 89Fan, Kai, 161Farah, R., 73Feng, Jie, 9Feng, Liu, 315Feng, Youji, 463Feng, Yu, 399Fu, Qiang, 215Fu, Qiang, 371Gao, Lei, 337Gao, Xuexin, 337Gao, Xuezhen, 337Guan, Hai-Tao, 437Guan, Lili, 99Guo, Xuefen, 225Guo, Ying, 117Han, Lingfei, 189Han, Shu-mei, 129Han, Yong, 129Han, Yong, 233He, Baimei, 81He, Haiyong, 117He, Kun, 239He, Ping, 25He, Qizhi, 189He, Ying, 145He, Yutong, 205Heng, Zhang, 315Hou, Bo, 117Hou, Jin, 145Hou, Jing-Zhou, 73Hou, Xiaobin, 247Hu, Chengping, 405Hu, Gaowu, 455Hu, Xiao-Yong, 371Huang, Huifang, 215Huang, Jin Xing, 489Huang, Li, 405Huang, Qianyi, 1Huang, Tengchao, 117Huo, Xin, 361Hyun, Suh-Kyung, 497Im, Annie, 73Isono, M., 327Jia, Jinpeng, 65Jiang, Feng, 381Jiang, He-qing, 25Jiang, Jiantao, 9Jiang, Nan, 361Jiang, Xi, 215Jiang, Yazhuo, 391Jiang, Youqin, 1Jin, Jing, 205Jin, Qing, 215Jin, Xue-fei, 479Kang, Chi-Dug, 497Kayacik, N., 41Kim, Hak-Bong, 497Kim, Sun-Hee, 497Knudson, C. L., 55Sobhakumari, A., 55Song, Yan, 65Song, Yanping, 109Su, Jiahao, 117Su, Zhiying, 353Sun, Chang-yu, 25Sun, Hui-ping, 197Sun, Liangzhang, 9Sun, Quan-Chao, 161Sun, Shi-bo, 239Sun, Yi, 391Sun, Yizhe, 345Tang, Na, 415Tang, Ya-ping, 415Tian, Bin-Qiang, 371Tian, Jing, 129Tian, Yaqiiong, 295Tian, Ye, 1Wan, Li, 161Wang, Dan, 429Wang, Dong, 99Wang, Feng, 345Wang, Gui-cong, 255Wang, Hao, 109Wang, Jiandong, 455Wang, Jian-Jun, 161Wang, Jian-rong, 33Wang, Jingdong, 1Wang, Lei, 361Wang, Lin-xian, 197Wang, Liqun, 205Wang, Longxiao, 1Wang, Ming, 455Wang, Ping, 17Wang, Ruoyu, 225Wang, Weihua, 345Wang, Xiaohong, 233Wang, Xi-Jing, 437Wang, Xuewei, 89Wang, Xuguang, 271Wang, Yadong, 137Wang, Yinhua, 295Wang, Yongsheng, 295Wang, Yu, 361Wang, Yue-shen, 129Wang, Zhe, 225Wei, Wang, 315Wu, Jiao, 197Wu, Wan-rui, 305Wu, Wei-gang, 415Xia, Cui, 145Xiao, Gao-ming, 197Xie, Jia, 109Xie, Tao, 447Xie, Yudi, 353Xing, Xin, 9Xu, Ye, 455Yan, Dayong, 399Yan, Jing, 145Yan, Qin, 463Yang, Hongying, 1Yang, Hongzhong, 81Yang, Jie, 295Yang, Jin-feng, 197Yang, Yeye, 145Yang, Zhenlin, 233Yang, Zhimin, 295Yantao, Han, 315Ye, Lei, 189Yin, Pei, 65You, Peidong, 215Yu, Bin, 361Yu, Chen, 17Yu, Wenliang, 429Yuan, Jun, 263Yuan, Li, 99Yuan, Qin, 215Zeng, Li, 415Zeng, Xiao-bing, 415Zhan, Lihui, 89Zhang, Burong, 345Zhang, Guoqiang, 233Zhang, Guo-ying, 33Zhang, Hong-xia, 25Zhang, Jian, 489Zhang, Jin, 9Zhang, Lin, 161Zhang, Liyuan, 1Zhang, Shaoqiang, 153Zhang, Shengchao, 263Zhang, Shiyang, 353Zhang, Ting, 189Zhang, Wei, 9Zhang, Yao, 429Zhang, Yiyan, 65Zhang, Yukin, 337Zhang, Yunjie, 109Zhang, Zengli, 295Zhao, Chunying, 455Zhao, Min, 353Zhao, Ping, 437Zhao, Qian, 153Zhao, Ruimin, 153Zhao, Yifan, 1Zheng, Guoxi, 145Zheng, Ruheng, 263Zheng, Ying, 171Zhong, Feng, 239Zhou, Bin, 9Zhou, Bo-ping, 415Zhou, Hui-cun, 255Zhou, Jie, 239Zhou, Qi, 99Zhu, Fu-qiang, 415Zhu, Jiankang, 137Zhu, Jianlong, 189Zhu, Kang, 145Zhu, Min, 137Zhuang, Liangjin, 353Zong, Shi, 479Zong, Wei, 17Zou, Dongling, 99Zou, Peng, 171Zou, Tiejun, 391Zou, Xiao Guang, 489 ABT-737, 65Acute lymphoblastic leukemia (ALL), 89Acute myeloid leukemia (AML), 73, 109, 215Advanced esophageal cancer, 129AKT1 substrate 1 (AKT1S1), 9Anexelekto (AXL), 295Apoptosis, 65, 145, 287, 345, 371, 399, 415, 429, 489Armadillo repeat-containing protein 8 (ARMC8), 381Astragaloside IV, 447Autophagy, 55, 287Belinostat, 327Bladder cancer, 391Brain metastases (BM), 523BRCA2, 247Breast cancer (BC), 233, 315, 455Cancer stem cells, 497CD133, 497Cell apoptosis, 89, 405Cell cycle, 171, 415Cell function, 239Cell growth, 89Cell invasion, 405Cell proliferation, 9, 145, 345, 399, 405, 463Cell viability, 429Centrosome localization, 247Cervical cancer, 99Chemoresistance, 279Chloroquine, 65Cisplatin, 81, 279Clinical samples, 239c-Myc, 161, 497Collagen triple helix repeat containing-1 (CTHRC1), 479Colon cancer, 137Colorectal cancer (CRC), 437, 447Combination treatment, 65COX2, 205Cullin 4B (CUL4B), 271Cyclic-AMP response element-binding protein (CREB), 171Cystatin B (CSTB), 489 2-Deoxy-d-glucose (2DG), 55Differentiation, 371DKK2, 89DOG1, 41Drug resistance, 447E-cadherin, 205Endoplasmic reticulum (ER) stress, 55, 327Epidermal growth factor receptor (EGFR), 55, 295Epithelial–mesenchymal transition (EMT), 17, 25, 33, 181, 305, 315, 337, 513Epithelial-to-mesenchymal transition (EMT), 81, 137, 225, 255ERK1/2, 279Erlotinib, 55Esophageal cancer (EC), 205, 247Etoposide, 73 Gastric cancer (GC), 17, 287, 489Gastrointestinal stromal tumors (GISTs), 41Gemcitabine plus vinorelbine, 129Glioblastoma (GBM), 117Glioma, 255GSK-3β, 145Head and neck squamous cell carcinoma (HNSCC), 55, 153Heat shock transcription factor 1 (HSF1), 109Hematopoietic pre-B-cell leukemia transcription factor (PBX)-interacting protein (HPIP), 153Hepatocarcinoma, 25Hepatocellular carcinoma (HCC), 239, 497, 513Herpesvirus entry mediator (HVEM), 189Hodgkin lymphoma (HL), 171HOXA1, 99HPIP, 33HS-5 cells, 215h SETD1A, 239Human renal cell carcinoma (RCC), 371Hypoxia, 255Immunosuppression, 189Insulin-like growth factor I (IGF-I), 225Insulin-like growth factor I receptor (IGF-IR), 225Invasion, 25, 137, 153, 181, 197, 263, 271, 353, 361, 381, 391, 437, 455, 479IQ motif containing GTPase-activating protein 3 (IQGAP3), 455JAG1, 391 gene, 41Krüppel-like factor 4 (KLF4), 81LIMD1, 247Long noncoding RNAs (lnc RNAs), 161Lung cancer, 161, 337, 405Lymphoma, 415Matrix metalloproteinases (MMPs), 263Metastasis, 161, 337, 463Micro RNA-1284, 429Micro RNA-155 (mi R-155), 415Micro RNA-16-1, 345Micro RNA-223 (mi R-223), 405Micro RNA-30a (mi R-30a), 225Micro RNAs (mi Rs), 353Migration, 455, 489mi R-10b, 99mi R-15a, 145mi R-183, 399mi R-187-5p, 89mi R-1908, 9mi R-34b, 109mi R-489, 391mi R-509, 233mi RNA-21, 371mi RNA-214, 129Mitoxantrone, 73Molecularly targeted drugs, 117m TOR, 371Multidrug resistance, 215Mutations, 41 Nasopharyngeal carcinoma (NPC), 145Newly diagnosed, 117NF-κB signal pathway, 405Non-small lung cancer, 81Non-small cell lung cancer (NSCLC), 9, 181, 197, 263, 271, 295, 345Non-small cell lung cancer cells (NSCLCs), 1 gene, 41PFTK1, 137, 181PI3K/Akt pathway, 429, 437, 513PI3K/Akt signaling, 305PI3K/Akt signaling pathway, 215, 361PI3K/Akt/m TOR pathway, 287, 489Platinum-based chemotherapy, 129Prognostic factors, 73Progression-free survival, 129Proliferation, 153, 171, 197, 337, 353, 361, 371, 381, 391, 455, 489Prostate cancer, 305Prostate cancer-associated transcription 6 (PCAT6), 161Pyruvate kinase isozyme type M2 (PKM2), 463Quality of life, 523Radiosensitization, 1Radiotherapy and temozolomide, 117Rap1b, 287Relapse, 73Renal cancer, 65Renal cell cancer, 327Renal cell carcinoma (RCC), 479Resistance, 81, 295REV7, 315Ribosomal protein (RP)–p53 pathway, 9Ritonavir, 327SAM- and SH3-domain containing 1 (SASH1), 17, 25SB431542, 1SCC25 cells, 399Second-line treatment, 129Signaling pathway, 463Simvastatin, 523SLC39A5 (ZIP5), 205SMMC-7721, 239Sparc/osteonectin, cwcv, and kazal-like domains proteoglycan (testican) 1 (SPOCK1), 437Src, 225STAT3, 371T cells, 189TIPE2, 255Tongue squamous cell carcinoma (TSCC), 399TRAIL, 497Transforming growth factor-β1 (TGF-β1), 1, 33, 315Transforming growth factor-β-induced 2 (TGFI2), 353Transforming growth factor-β receptor 2 (TGFBR2), 415Treatment, 117Triple-negative breast cancer (TNBC), 233Tumor necrosis factor-α (TNF-α), 233Tumor necrosis factor-α (TNF-α)-induced protein 8-like 2 (TNFAIP8L2, TIPE2), 305Tumor suppressor, 99Tumorigenesis, 263Ubiquitin-conjugating enzyme E2T (UBE2T), 361Ubiquitin-specific peptidase 17 (USP17), 263Ultraconserved element 338 (uc.338), 337Upregulated gene 11 (URG11), 197Whole-brain radiation therapy (WBRT), 523Wnt pathway, 109Wnt/β-catenin pathway, 271Wnt/β-catenin signaling, 479Wnt/β-catenin signaling pathway, 197Xenograft, 205Zinc, 205Agha, M., 137Bai, Mingzhu, 267Bai, Yun, 205Boyiadzis, M., 137Cao, Chu-yu, 79Chaudhri, S., 291Chen, Gang, 119Chen, Min, 61Chen, Xiangming, 197Choghaei, E., 69Copur, M. H., 67Lee, S.-J., 93Lee, T.-H., 391Lee, W.-S., 115Li, B., 131Li, D., 141Li, H., 237Li, H., 149Li, H., 171Li, S., 303Li, S., 555Li, X., 323Li, X., 35Li, X., 149Li, Z., 77Li, Z.-H., 125Li, Z., 149Li, Z.-L., 125Liang, J., 225Liang, Y., 149Liao, F., 203Libby, E., 93Lim, D.-H., 381Lin, L., 125Liu, B., 131Liu, H., 171Liu, H., 519Liu, S.-Q., 573Liu, T., 125Liu, W., 35Liu, X.-K., 125Liu, Z., 131Liu, Z., 563Long, Y., 149Loudon, J. R., 287Milione, M., 403Mirzayans, R., 265Misawa, A., 23Mittal, B., 165Miwa, N., 203Mochinaga, S., 111, 511Moghadam, M. J., 349Montazeri, V., 375Moon, A., 297Mori, K., 543Morita, J., 479Mozzetti, S., 13Murray, D., 265Myung, S. I., 471Naito, Y., 543Nakamura, T., 85Nakamura, T., 111Nakano, K., 463Nakano, Y., 511Nakashima, M., 463Nam, D.-H., 381Naoe, M., 479Nation, P. V., 105Shao, Q., 225Sharma, A., 365Sharma, K., 165Sharma, M., 365Shi, K., 77Shichijo, T., 479Shukla, Y., 245Sil, H., 335Simizu, S., 445Singh, M., 245Singh, R., 245Somoza-Martín, J. R., 99Togano, T., 463Tomida, A., 23Tong, G.-Z., 323Tsuboi, S., 85Tyagi, S., 245Uchida, J., 399Uchiyama, K., 543Um, H.-D., 381Ureshino, N., 111Uysal, M., 259von Carlowitz, I., 349Wallace, E., 349Wang, A., 303Wang, B., 349Wang, G., 193Wang, H., 501Wang, J., 501Wang, M., 535Wang, R., 141Wang, T., 171Wang, T., 193Wang, W., 141Wang, Y., 501Wang, Y., 501Watanabe, M., 463Watanabe, T., 23, 463Xiao, H., 35Xie, Q., 555Xie, X., 131Xing, F., 501Xioa, M.-C., 535Xu, C., 77Xu, M.-K., 125Xun, P., 171Yagi, N., 543Yakabe, T., 511Yamaguchi, A., 527Yamamoto, H., 85Yamaya, K., 85Yan, W., 563Yang, B.-F., 323Yang, H.-A., 535Yang, H.-Y., 391Yang, J., 519Yang, L., 35Yang, U., 391Yang, W.-F., 125Yang, Y., 77Yang, Y., 225Yang, Y., 501Yang, Y.-J., 323Yang, Z. P., 269Clézardin, P., 173 (357*)Costarelli, L, 409Cui, L., 305Dan, L., 593Daniels, B. H., 221Giacconi, R., 409Goi, T., 541Gong, Y., 437Grossmann, M. J., 287Hosono, T., 575Hosono-Fukao, T., 575Hsieh, C.-Y., 279Hu, H., 561Hu, Z., 305Huang, C.-Y., 279Huang, F., 1Huang, G., 31Huang, H., 437Huang, H.-Z., 377Huang, K., 229Huang, L., 203Huang, X.-Y., 503Iitsuka, Y., 575Iwamoto, S., 493Jai, T., 73Jain, M., 41Jansen, J. It is the responsibility of the corresponding author to ensure that this occurs. Mercer American Continent: Edward Chu University of Pittsburgh Cancer Institute, USAEmail: This e-mail address is being protected from spambots. Workman, CRC Center for Cancer Therapeutics, UKAsia and Pacific Rim: Kazuo , RIKEN, Japan E. S., 1Cui, Ya Jie, 275Du, Xilin, 43Du, Yanwei, 229Eren, M., 1Falahati, M., 61Fan, Li-Qiao, 129Fan, Yaohua, 219Fang, Weiyi, 61Fang, Yong, 219Farah, R., 137Feng, Youji, 267Gao, Ji, 321Gao, Jianjun, 43Gauchan, D., 1Ge, Honglei, 171Ghosh-Laskar, S., 183Gong, Weihong, 283Gu, Hongli, 61Gu, Yuanting, 165Guo, Baofeng, 229Guo, Ensong, 119Guo, Meng, 291Guo, Yihang, 303Hasanpour, M., 69Hashemi, Z. A., 55, 407Lu, S., 225Lu, S., 519Luo, J., 563Lv, Z., 131Lyon, M. A., 165Malki, A., 275Mariani, M., 13Matsumoto, T., 543Mc Ewan, A. N., 287Nishino, K., 399 Noh, D.-Y., 297Noshiro, H., 511Ogawa, Y., 479Ohyama, C., 85Okahashi, T., 511Okamoto, A., 85Okyuama, T., 399Osada, H., 445Park, B.-J., 391Park, C.-H., 115Park, S.-J., 115Park, S.-Y., 455Park, Y.-L., 115Pérez-Sayáns, M., 45Pillai, R., 99Po, H. K., 471Riauka, T., 287Saitoh, H., 85Saitoh, Y., 203Sakamoto, N., 543Sato, A., 217Sato, T., 85Satyam, A., 365Sayar, H., 93Scambia, G., 13Sen, T., 335Şener, G., 259Seol, H. L., 487Yi, E.-Y., 455Yin, J., 131Yoneyama, T., 85Yoo, H. J., 381Yosikawa, T., 543Youssef, A., 275Yu, M., 149Yu, Y., 141Yun, H.-Y., 237Zargar, S. E., 269Gu, P., 133Guan, H., 117Guan, X.-X., 503Guillet, B., 173Gunduz, E., 509Gunduz, M., 509Guo, J., 519Habler, L., 537Haghighi, M.

||

At the time of submission, you will be asked to confirm that you will pay the relatively inexpensive open access fee of $600.00 for articles up to 5 printed pages, $1,000.00 for 5-12 printed pages and $50.00 for each additional printed page over 12 pages.

There is a $50.00 administration fee that will be added to the Open Access fee. D., 549Paz-y-Miño, C., 395Paz-y-Miño, N., 395Perbellini, L., 409Peters, W. M., 349Peyruchaud, O., 173 (357*)Piacenza, F., 409Pierpaoli, S., 409Piersiak, T., 419Podzimek, T., 163Poučková, P., 163Prasanna, R., 461Radpour, R., 57Raibowol, K., 95Ray, A., 269Reddanna, P., 243Reimann, K., 343Ren, Y., 1Rha, S.

In addition, submissions that investigate the potential role of herbal/botanical medicines in preclinical and clinical cancer therapy are welcomed; however, it will be important to document that these medicines are of high quality, with confirmation of consistency. N., 243, 481Sasaki, A., 509Sawai, K., 541Scharovsky, O. K., 293Vinothini, G., 193von Deimling, A., 95, 469Wang, A., 377Wang, C., 561Wang, H., 359Wang, H., 519Wang, J., 359Wang, J.-G., 377Wang, M.-W., 133Wang, Y., 401Wang, Z., 359Wen, W., 73Wessner, B., 83Wimberger, P., 343Wiritsch, M., 83Wojtowicz, M., 127Wolowiec, D., 127Wu, Y., 1Wurm, R., 469Xiao, C., 561Xing, L., 1Xu, C., 1Xu, J.-H., 377Xu, Y., 359Xue, M., 503Xue, X., 561Yamaguchi, A., 541Yamaoka, T., 337Yamochi, T., 153Yan, Z., 519Yang, J., 437Yang, Y., 1Yang, Y., 519Yildiz, R., 583Yoo, B. S., 257 Asawakarn, S., 301 Aurello, P., 405 Bae, K.-H., 601 Barkhout, M., 347 Bauer, S.

In addition to original peer-reviewed articles, the journal also welcomes timely reviews and/or commentaries on topics that focus on preclinical, translational, and/or clinical cancer therapeutics This e-mail address is being protected from spambots. G., 601Schumacher, U., 387Scott, A., 229Seki, T., 575Sevinc, A., 583Seyedabadi, M., 221Shah, S., 95Shichijo, T., 153, 493Shimada, C., 529Shirai, T., 337Siffert, W., 343Singh, H., 41, 329Singh, M. M., 293Singh, V., 293Sinn, B., 469Škvor, J., 163Sokolchik, I., 269Song, J.-C., 259Song, Y.-S., 453Souček, J., 163Srinivasan, R., 549Srivastava, S., 329Steed, P., 229Stehlík, J., 163Sturlan, S., 83Su, Z., 73Sugiyama, T., 337Sun, X.-F., 133Suzuki, E., 529Suzuki, H., 409Suzuki, K., 95Szteblich, A., 127 Taib, N.

All authors must also agree to the addition of new authors. Kim, University of Ulsan College of Medicine, Korea T. Kim, University of Ulsan College of Medicine, Korea N. A., 73Du, Shuangkuan, 391Duggal, S., 73El-Hamamsy, M., 523Ellidokuz, H., 41Elwakil, H., 523Fan, Hua, 89Fan, Kai, 161Farah, R., 73Feng, Jie, 9Feng, Liu, 315Feng, Youji, 463Feng, Yu, 399Fu, Qiang, 215Fu, Qiang, 371Gao, Lei, 337Gao, Xuexin, 337Gao, Xuezhen, 337Guan, Hai-Tao, 437Guan, Lili, 99Guo, Xuefen, 225Guo, Ying, 117Han, Lingfei, 189Han, Shu-mei, 129Han, Yong, 129Han, Yong, 233He, Baimei, 81He, Haiyong, 117He, Kun, 239He, Ping, 25He, Qizhi, 189He, Ying, 145He, Yutong, 205Heng, Zhang, 315Hou, Bo, 117Hou, Jin, 145Hou, Jing-Zhou, 73Hou, Xiaobin, 247Hu, Chengping, 405Hu, Gaowu, 455Hu, Xiao-Yong, 371Huang, Huifang, 215Huang, Jin Xing, 489Huang, Li, 405Huang, Qianyi, 1Huang, Tengchao, 117Huo, Xin, 361Hyun, Suh-Kyung, 497Im, Annie, 73Isono, M., 327Jia, Jinpeng, 65Jiang, Feng, 381Jiang, He-qing, 25Jiang, Jiantao, 9Jiang, Nan, 361Jiang, Xi, 215Jiang, Yazhuo, 391Jiang, Youqin, 1Jin, Jing, 205Jin, Qing, 215Jin, Xue-fei, 479Kang, Chi-Dug, 497Kayacik, N., 41Kim, Hak-Bong, 497Kim, Sun-Hee, 497Knudson, C. L., 55Sobhakumari, A., 55Song, Yan, 65Song, Yanping, 109Su, Jiahao, 117Su, Zhiying, 353Sun, Chang-yu, 25Sun, Hui-ping, 197Sun, Liangzhang, 9Sun, Quan-Chao, 161Sun, Shi-bo, 239Sun, Yi, 391Sun, Yizhe, 345Tang, Na, 415Tang, Ya-ping, 415Tian, Bin-Qiang, 371Tian, Jing, 129Tian, Yaqiiong, 295Tian, Ye, 1Wan, Li, 161Wang, Dan, 429Wang, Dong, 99Wang, Feng, 345Wang, Gui-cong, 255Wang, Hao, 109Wang, Jiandong, 455Wang, Jian-Jun, 161Wang, Jian-rong, 33Wang, Jingdong, 1Wang, Lei, 361Wang, Lin-xian, 197Wang, Liqun, 205Wang, Longxiao, 1Wang, Ming, 455Wang, Ping, 17Wang, Ruoyu, 225Wang, Weihua, 345Wang, Xiaohong, 233Wang, Xi-Jing, 437Wang, Xuewei, 89Wang, Xuguang, 271Wang, Yadong, 137Wang, Yinhua, 295Wang, Yongsheng, 295Wang, Yu, 361Wang, Yue-shen, 129Wang, Zhe, 225Wei, Wang, 315Wu, Jiao, 197Wu, Wan-rui, 305Wu, Wei-gang, 415Xia, Cui, 145Xiao, Gao-ming, 197Xie, Jia, 109Xie, Tao, 447Xie, Yudi, 353Xing, Xin, 9Xu, Ye, 455Yan, Dayong, 399Yan, Jing, 145Yan, Qin, 463Yang, Hongying, 1Yang, Hongzhong, 81Yang, Jie, 295Yang, Jin-feng, 197Yang, Yeye, 145Yang, Zhenlin, 233Yang, Zhimin, 295Yantao, Han, 315Ye, Lei, 189Yin, Pei, 65You, Peidong, 215Yu, Bin, 361Yu, Chen, 17Yu, Wenliang, 429Yuan, Jun, 263Yuan, Li, 99Yuan, Qin, 215Zeng, Li, 415Zeng, Xiao-bing, 415Zhan, Lihui, 89Zhang, Burong, 345Zhang, Guoqiang, 233Zhang, Guo-ying, 33Zhang, Hong-xia, 25Zhang, Jian, 489Zhang, Jin, 9Zhang, Lin, 161Zhang, Liyuan, 1Zhang, Shaoqiang, 153Zhang, Shengchao, 263Zhang, Shiyang, 353Zhang, Ting, 189Zhang, Wei, 9Zhang, Yao, 429Zhang, Yiyan, 65Zhang, Yukin, 337Zhang, Yunjie, 109Zhang, Zengli, 295Zhao, Chunying, 455Zhao, Min, 353Zhao, Ping, 437Zhao, Qian, 153Zhao, Ruimin, 153Zhao, Yifan, 1Zheng, Guoxi, 145Zheng, Ruheng, 263Zheng, Ying, 171Zhong, Feng, 239Zhou, Bin, 9Zhou, Bo-ping, 415Zhou, Hui-cun, 255Zhou, Jie, 239Zhou, Qi, 99Zhu, Fu-qiang, 415Zhu, Jiankang, 137Zhu, Jianlong, 189Zhu, Kang, 145Zhu, Min, 137Zhuang, Liangjin, 353Zong, Shi, 479Zong, Wei, 17Zou, Dongling, 99Zou, Peng, 171Zou, Tiejun, 391Zou, Xiao Guang, 489 ABT-737, 65Acute lymphoblastic leukemia (ALL), 89Acute myeloid leukemia (AML), 73, 109, 215Advanced esophageal cancer, 129AKT1 substrate 1 (AKT1S1), 9Anexelekto (AXL), 295Apoptosis, 65, 145, 287, 345, 371, 399, 415, 429, 489Armadillo repeat-containing protein 8 (ARMC8), 381Astragaloside IV, 447Autophagy, 55, 287Belinostat, 327Bladder cancer, 391Brain metastases (BM), 523BRCA2, 247Breast cancer (BC), 233, 315, 455Cancer stem cells, 497CD133, 497Cell apoptosis, 89, 405Cell cycle, 171, 415Cell function, 239Cell growth, 89Cell invasion, 405Cell proliferation, 9, 145, 345, 399, 405, 463Cell viability, 429Centrosome localization, 247Cervical cancer, 99Chemoresistance, 279Chloroquine, 65Cisplatin, 81, 279Clinical samples, 239c-Myc, 161, 497Collagen triple helix repeat containing-1 (CTHRC1), 479Colon cancer, 137Colorectal cancer (CRC), 437, 447Combination treatment, 65COX2, 205Cullin 4B (CUL4B), 271Cyclic-AMP response element-binding protein (CREB), 171Cystatin B (CSTB), 489 2-Deoxy-d-glucose (2DG), 55Differentiation, 371DKK2, 89DOG1, 41Drug resistance, 447E-cadherin, 205Endoplasmic reticulum (ER) stress, 55, 327Epidermal growth factor receptor (EGFR), 55, 295Epithelial–mesenchymal transition (EMT), 17, 25, 33, 181, 305, 315, 337, 513Epithelial-to-mesenchymal transition (EMT), 81, 137, 225, 255ERK1/2, 279Erlotinib, 55Esophageal cancer (EC), 205, 247Etoposide, 73 Gastric cancer (GC), 17, 287, 489Gastrointestinal stromal tumors (GISTs), 41Gemcitabine plus vinorelbine, 129Glioblastoma (GBM), 117Glioma, 255GSK-3β, 145Head and neck squamous cell carcinoma (HNSCC), 55, 153Heat shock transcription factor 1 (HSF1), 109Hematopoietic pre-B-cell leukemia transcription factor (PBX)-interacting protein (HPIP), 153Hepatocarcinoma, 25Hepatocellular carcinoma (HCC), 239, 497, 513Herpesvirus entry mediator (HVEM), 189Hodgkin lymphoma (HL), 171HOXA1, 99HPIP, 33HS-5 cells, 215h SETD1A, 239Human renal cell carcinoma (RCC), 371Hypoxia, 255Immunosuppression, 189Insulin-like growth factor I (IGF-I), 225Insulin-like growth factor I receptor (IGF-IR), 225Invasion, 25, 137, 153, 181, 197, 263, 271, 353, 361, 381, 391, 437, 455, 479IQ motif containing GTPase-activating protein 3 (IQGAP3), 455JAG1, 391 gene, 41Krüppel-like factor 4 (KLF4), 81LIMD1, 247Long noncoding RNAs (lnc RNAs), 161Lung cancer, 161, 337, 405Lymphoma, 415Matrix metalloproteinases (MMPs), 263Metastasis, 161, 337, 463Micro RNA-1284, 429Micro RNA-155 (mi R-155), 415Micro RNA-16-1, 345Micro RNA-223 (mi R-223), 405Micro RNA-30a (mi R-30a), 225Micro RNAs (mi Rs), 353Migration, 455, 489mi R-10b, 99mi R-15a, 145mi R-183, 399mi R-187-5p, 89mi R-1908, 9mi R-34b, 109mi R-489, 391mi R-509, 233mi RNA-21, 371mi RNA-214, 129Mitoxantrone, 73Molecularly targeted drugs, 117m TOR, 371Multidrug resistance, 215Mutations, 41 Nasopharyngeal carcinoma (NPC), 145Newly diagnosed, 117NF-κB signal pathway, 405Non-small lung cancer, 81Non-small cell lung cancer (NSCLC), 9, 181, 197, 263, 271, 295, 345Non-small cell lung cancer cells (NSCLCs), 1 gene, 41PFTK1, 137, 181PI3K/Akt pathway, 429, 437, 513PI3K/Akt signaling, 305PI3K/Akt signaling pathway, 215, 361PI3K/Akt/m TOR pathway, 287, 489Platinum-based chemotherapy, 129Prognostic factors, 73Progression-free survival, 129Proliferation, 153, 171, 197, 337, 353, 361, 371, 381, 391, 455, 489Prostate cancer, 305Prostate cancer-associated transcription 6 (PCAT6), 161Pyruvate kinase isozyme type M2 (PKM2), 463Quality of life, 523Radiosensitization, 1Radiotherapy and temozolomide, 117Rap1b, 287Relapse, 73Renal cancer, 65Renal cell cancer, 327Renal cell carcinoma (RCC), 479Resistance, 81, 295REV7, 315Ribosomal protein (RP)–p53 pathway, 9Ritonavir, 327SAM- and SH3-domain containing 1 (SASH1), 17, 25SB431542, 1SCC25 cells, 399Second-line treatment, 129Signaling pathway, 463Simvastatin, 523SLC39A5 (ZIP5), 205SMMC-7721, 239Sparc/osteonectin, cwcv, and kazal-like domains proteoglycan (testican) 1 (SPOCK1), 437Src, 225STAT3, 371T cells, 189TIPE2, 255Tongue squamous cell carcinoma (TSCC), 399TRAIL, 497Transforming growth factor-β1 (TGF-β1), 1, 33, 315Transforming growth factor-β-induced 2 (TGFI2), 353Transforming growth factor-β receptor 2 (TGFBR2), 415Treatment, 117Triple-negative breast cancer (TNBC), 233Tumor necrosis factor-α (TNF-α), 233Tumor necrosis factor-α (TNF-α)-induced protein 8-like 2 (TNFAIP8L2, TIPE2), 305Tumor suppressor, 99Tumorigenesis, 263Ubiquitin-conjugating enzyme E2T (UBE2T), 361Ubiquitin-specific peptidase 17 (USP17), 263Ultraconserved element 338 (uc.338), 337Upregulated gene 11 (URG11), 197Whole-brain radiation therapy (WBRT), 523Wnt pathway, 109Wnt/β-catenin pathway, 271Wnt/β-catenin signaling, 479Wnt/β-catenin signaling pathway, 197Xenograft, 205Zinc, 205Agha, M., 137Bai, Mingzhu, 267Bai, Yun, 205Boyiadzis, M., 137Cao, Chu-yu, 79Chaudhri, S., 291Chen, Gang, 119Chen, Min, 61Chen, Xiangming, 197Choghaei, E., 69Copur, M. H., 67Lee, S.-J., 93Lee, T.-H., 391Lee, W.-S., 115Li, B., 131Li, D., 141Li, H., 237Li, H., 149Li, H., 171Li, S., 303Li, S., 555Li, X., 323Li, X., 35Li, X., 149Li, Z., 77Li, Z.-H., 125Li, Z., 149Li, Z.-L., 125Liang, J., 225Liang, Y., 149Liao, F., 203Libby, E., 93Lim, D.-H., 381Lin, L., 125Liu, B., 131Liu, H., 171Liu, H., 519Liu, S.-Q., 573Liu, T., 125Liu, W., 35Liu, X.-K., 125Liu, Z., 131Liu, Z., 563Long, Y., 149Loudon, J. R., 287Milione, M., 403Mirzayans, R., 265Misawa, A., 23Mittal, B., 165Miwa, N., 203Mochinaga, S., 111, 511Moghadam, M. J., 349Montazeri, V., 375Moon, A., 297Mori, K., 543Morita, J., 479Mozzetti, S., 13Murray, D., 265Myung, S. I., 471Naito, Y., 543Nakamura, T., 85Nakamura, T., 111Nakano, K., 463Nakano, Y., 511Nakashima, M., 463Nam, D.-H., 381Naoe, M., 479Nation, P. V., 105Shao, Q., 225Sharma, A., 365Sharma, K., 165Sharma, M., 365Shi, K., 77Shichijo, T., 479Shukla, Y., 245Sil, H., 335Simizu, S., 445Singh, M., 245Singh, R., 245Somoza-Martín, J. R., 99Togano, T., 463Tomida, A., 23Tong, G.-Z., 323Tsuboi, S., 85Tyagi, S., 245Uchida, J., 399Uchiyama, K., 543Um, H.-D., 381Ureshino, N., 111Uysal, M., 259von Carlowitz, I., 349Wallace, E., 349Wang, A., 303Wang, B., 349Wang, G., 193Wang, H., 501Wang, J., 501Wang, M., 535Wang, R., 141Wang, T., 171Wang, T., 193Wang, W., 141Wang, Y., 501Wang, Y., 501Watanabe, M., 463Watanabe, T., 23, 463Xiao, H., 35Xie, Q., 555Xie, X., 131Xing, F., 501Xioa, M.-C., 535Xu, C., 77Xu, M.-K., 125Xun, P., 171Yagi, N., 543Yakabe, T., 511Yamaguchi, A., 527Yamamoto, H., 85Yamaya, K., 85Yan, W., 563Yang, B.-F., 323Yang, H.-A., 535Yang, H.-Y., 391Yang, J., 519Yang, L., 35Yang, U., 391Yang, W.-F., 125Yang, Y., 77Yang, Y., 225Yang, Y., 501Yang, Y.-J., 323Yang, Z. P., 269Clézardin, P., 173 (357*)Costarelli, L, 409Cui, L., 305Dan, L., 593Daniels, B. H., 221Giacconi, R., 409Goi, T., 541Gong, Y., 437Grossmann, M. J., 287Hosono, T., 575Hosono-Fukao, T., 575Hsieh, C.-Y., 279Hu, H., 561Hu, Z., 305Huang, C.-Y., 279Huang, F., 1Huang, G., 31Huang, H., 437Huang, H.-Z., 377Huang, K., 229Huang, L., 203Huang, X.-Y., 503Iitsuka, Y., 575Iwamoto, S., 493Jai, T., 73Jain, M., 41Jansen, J.

,000.00 for 5-12 printed pages and .00 for each additional printed page over 12 pages. There is a .00 administration fee that will be added to the Open Access fee. D., 549Paz-y-Miño, C., 395Paz-y-Miño, N., 395Perbellini, L., 409Peters, W. M., 349Peyruchaud, O., 173 (357*)Piacenza, F., 409Pierpaoli, S., 409Piersiak, T., 419Podzimek, T., 163Poučková, P., 163Prasanna, R., 461Radpour, R., 57Raibowol, K., 95Ray, A., 269Reddanna, P., 243Reimann, K., 343Ren, Y., 1Rha, S. In addition, submissions that investigate the potential role of herbal/botanical medicines in preclinical and clinical cancer therapy are welcomed; however, it will be important to document that these medicines are of high quality, with confirmation of consistency. N., 243, 481Sasaki, A., 509Sawai, K., 541Scharovsky, O. K., 293Vinothini, G., 193von Deimling, A., 95, 469Wang, A., 377Wang, C., 561Wang, H., 359Wang, H., 519Wang, J., 359Wang, J.-G., 377Wang, M.-W., 133Wang, Y., 401Wang, Z., 359Wen, W., 73Wessner, B., 83Wimberger, P., 343Wiritsch, M., 83Wojtowicz, M., 127Wolowiec, D., 127Wu, Y., 1Wurm, R., 469Xiao, C., 561Xing, L., 1Xu, C., 1Xu, J.-H., 377Xu, Y., 359Xue, M., 503Xue, X., 561Yamaguchi, A., 541Yamaoka, T., 337Yamochi, T., 153Yan, Z., 519Yang, J., 437Yang, Y., 1Yang, Y., 519Yildiz, R., 583Yoo, B. S., 257 Asawakarn, S., 301 Aurello, P., 405 Bae, K.-H., 601 Barkhout, M., 347 Bauer, S. In addition to original peer-reviewed articles, the journal also welcomes timely reviews and/or commentaries on topics that focus on preclinical, translational, and/or clinical cancer therapeutics This e-mail address is being protected from spambots. G., 601Schumacher, U., 387Scott, A., 229Seki, T., 575Sevinc, A., 583Seyedabadi, M., 221Shah, S., 95Shichijo, T., 153, 493Shimada, C., 529Shirai, T., 337Siffert, W., 343Singh, H., 41, 329Singh, M. M., 293Singh, V., 293Sinn, B., 469Škvor, J., 163Sokolchik, I., 269Song, J.-C., 259Song, Y.-S., 453Souček, J., 163Srinivasan, R., 549Srivastava, S., 329Steed, P., 229Stehlík, J., 163Sturlan, S., 83Su, Z., 73Sugiyama, T., 337Sun, X.-F., 133Suzuki, E., 529Suzuki, H., 409Suzuki, K., 95Szteblich, A., 127 Taib, N. All authors must also agree to the addition of new authors. Kim, University of Ulsan College of Medicine, Korea T. Kim, University of Ulsan College of Medicine, Korea N. A., 73Du, Shuangkuan, 391Duggal, S., 73El-Hamamsy, M., 523Ellidokuz, H., 41Elwakil, H., 523Fan, Hua, 89Fan, Kai, 161Farah, R., 73Feng, Jie, 9Feng, Liu, 315Feng, Youji, 463Feng, Yu, 399Fu, Qiang, 215Fu, Qiang, 371Gao, Lei, 337Gao, Xuexin, 337Gao, Xuezhen, 337Guan, Hai-Tao, 437Guan, Lili, 99Guo, Xuefen, 225Guo, Ying, 117Han, Lingfei, 189Han, Shu-mei, 129Han, Yong, 129Han, Yong, 233He, Baimei, 81He, Haiyong, 117He, Kun, 239He, Ping, 25He, Qizhi, 189He, Ying, 145He, Yutong, 205Heng, Zhang, 315Hou, Bo, 117Hou, Jin, 145Hou, Jing-Zhou, 73Hou, Xiaobin, 247Hu, Chengping, 405Hu, Gaowu, 455Hu, Xiao-Yong, 371Huang, Huifang, 215Huang, Jin Xing, 489Huang, Li, 405Huang, Qianyi, 1Huang, Tengchao, 117Huo, Xin, 361Hyun, Suh-Kyung, 497Im, Annie, 73Isono, M., 327Jia, Jinpeng, 65Jiang, Feng, 381Jiang, He-qing, 25Jiang, Jiantao, 9Jiang, Nan, 361Jiang, Xi, 215Jiang, Yazhuo, 391Jiang, Youqin, 1Jin, Jing, 205Jin, Qing, 215Jin, Xue-fei, 479Kang, Chi-Dug, 497Kayacik, N., 41Kim, Hak-Bong, 497Kim, Sun-Hee, 497Knudson, C. L., 55Sobhakumari, A., 55Song, Yan, 65Song, Yanping, 109Su, Jiahao, 117Su, Zhiying, 353Sun, Chang-yu, 25Sun, Hui-ping, 197Sun, Liangzhang, 9Sun, Quan-Chao, 161Sun, Shi-bo, 239Sun, Yi, 391Sun, Yizhe, 345Tang, Na, 415Tang, Ya-ping, 415Tian, Bin-Qiang, 371Tian, Jing, 129Tian, Yaqiiong, 295Tian, Ye, 1Wan, Li, 161Wang, Dan, 429Wang, Dong, 99Wang, Feng, 345Wang, Gui-cong, 255Wang, Hao, 109Wang, Jiandong, 455Wang, Jian-Jun, 161Wang, Jian-rong, 33Wang, Jingdong, 1Wang, Lei, 361Wang, Lin-xian, 197Wang, Liqun, 205Wang, Longxiao, 1Wang, Ming, 455Wang, Ping, 17Wang, Ruoyu, 225Wang, Weihua, 345Wang, Xiaohong, 233Wang, Xi-Jing, 437Wang, Xuewei, 89Wang, Xuguang, 271Wang, Yadong, 137Wang, Yinhua, 295Wang, Yongsheng, 295Wang, Yu, 361Wang, Yue-shen, 129Wang, Zhe, 225Wei, Wang, 315Wu, Jiao, 197Wu, Wan-rui, 305Wu, Wei-gang, 415Xia, Cui, 145Xiao, Gao-ming, 197Xie, Jia, 109Xie, Tao, 447Xie, Yudi, 353Xing, Xin, 9Xu, Ye, 455Yan, Dayong, 399Yan, Jing, 145Yan, Qin, 463Yang, Hongying, 1Yang, Hongzhong, 81Yang, Jie, 295Yang, Jin-feng, 197Yang, Yeye, 145Yang, Zhenlin, 233Yang, Zhimin, 295Yantao, Han, 315Ye, Lei, 189Yin, Pei, 65You, Peidong, 215Yu, Bin, 361Yu, Chen, 17Yu, Wenliang, 429Yuan, Jun, 263Yuan, Li, 99Yuan, Qin, 215Zeng, Li, 415Zeng, Xiao-bing, 415Zhan, Lihui, 89Zhang, Burong, 345Zhang, Guoqiang, 233Zhang, Guo-ying, 33Zhang, Hong-xia, 25Zhang, Jian, 489Zhang, Jin, 9Zhang, Lin, 161Zhang, Liyuan, 1Zhang, Shaoqiang, 153Zhang, Shengchao, 263Zhang, Shiyang, 353Zhang, Ting, 189Zhang, Wei, 9Zhang, Yao, 429Zhang, Yiyan, 65Zhang, Yukin, 337Zhang, Yunjie, 109Zhang, Zengli, 295Zhao, Chunying, 455Zhao, Min, 353Zhao, Ping, 437Zhao, Qian, 153Zhao, Ruimin, 153Zhao, Yifan, 1Zheng, Guoxi, 145Zheng, Ruheng, 263Zheng, Ying, 171Zhong, Feng, 239Zhou, Bin, 9Zhou, Bo-ping, 415Zhou, Hui-cun, 255Zhou, Jie, 239Zhou, Qi, 99Zhu, Fu-qiang, 415Zhu, Jiankang, 137Zhu, Jianlong, 189Zhu, Kang, 145Zhu, Min, 137Zhuang, Liangjin, 353Zong, Shi, 479Zong, Wei, 17Zou, Dongling, 99Zou, Peng, 171Zou, Tiejun, 391Zou, Xiao Guang, 489 ABT-737, 65Acute lymphoblastic leukemia (ALL), 89Acute myeloid leukemia (AML), 73, 109, 215Advanced esophageal cancer, 129AKT1 substrate 1 (AKT1S1), 9Anexelekto (AXL), 295Apoptosis, 65, 145, 287, 345, 371, 399, 415, 429, 489Armadillo repeat-containing protein 8 (ARMC8), 381Astragaloside IV, 447Autophagy, 55, 287Belinostat, 327Bladder cancer, 391Brain metastases (BM), 523BRCA2, 247Breast cancer (BC), 233, 315, 455Cancer stem cells, 497CD133, 497Cell apoptosis, 89, 405Cell cycle, 171, 415Cell function, 239Cell growth, 89Cell invasion, 405Cell proliferation, 9, 145, 345, 399, 405, 463Cell viability, 429Centrosome localization, 247Cervical cancer, 99Chemoresistance, 279Chloroquine, 65Cisplatin, 81, 279Clinical samples, 239c-Myc, 161, 497Collagen triple helix repeat containing-1 (CTHRC1), 479Colon cancer, 137Colorectal cancer (CRC), 437, 447Combination treatment, 65COX2, 205Cullin 4B (CUL4B), 271Cyclic-AMP response element-binding protein (CREB), 171Cystatin B (CSTB), 489 2-Deoxy-d-glucose (2DG), 55Differentiation, 371DKK2, 89DOG1, 41Drug resistance, 447E-cadherin, 205Endoplasmic reticulum (ER) stress, 55, 327Epidermal growth factor receptor (EGFR), 55, 295Epithelial–mesenchymal transition (EMT), 17, 25, 33, 181, 305, 315, 337, 513Epithelial-to-mesenchymal transition (EMT), 81, 137, 225, 255ERK1/2, 279Erlotinib, 55Esophageal cancer (EC), 205, 247Etoposide, 73 Gastric cancer (GC), 17, 287, 489Gastrointestinal stromal tumors (GISTs), 41Gemcitabine plus vinorelbine, 129Glioblastoma (GBM), 117Glioma, 255GSK-3β, 145Head and neck squamous cell carcinoma (HNSCC), 55, 153Heat shock transcription factor 1 (HSF1), 109Hematopoietic pre-B-cell leukemia transcription factor (PBX)-interacting protein (HPIP), 153Hepatocarcinoma, 25Hepatocellular carcinoma (HCC), 239, 497, 513Herpesvirus entry mediator (HVEM), 189Hodgkin lymphoma (HL), 171HOXA1, 99HPIP, 33HS-5 cells, 215h SETD1A, 239Human renal cell carcinoma (RCC), 371Hypoxia, 255Immunosuppression, 189Insulin-like growth factor I (IGF-I), 225Insulin-like growth factor I receptor (IGF-IR), 225Invasion, 25, 137, 153, 181, 197, 263, 271, 353, 361, 381, 391, 437, 455, 479IQ motif containing GTPase-activating protein 3 (IQGAP3), 455JAG1, 391 gene, 41Krüppel-like factor 4 (KLF4), 81LIMD1, 247Long noncoding RNAs (lnc RNAs), 161Lung cancer, 161, 337, 405Lymphoma, 415Matrix metalloproteinases (MMPs), 263Metastasis, 161, 337, 463Micro RNA-1284, 429Micro RNA-155 (mi R-155), 415Micro RNA-16-1, 345Micro RNA-223 (mi R-223), 405Micro RNA-30a (mi R-30a), 225Micro RNAs (mi Rs), 353Migration, 455, 489mi R-10b, 99mi R-15a, 145mi R-183, 399mi R-187-5p, 89mi R-1908, 9mi R-34b, 109mi R-489, 391mi R-509, 233mi RNA-21, 371mi RNA-214, 129Mitoxantrone, 73Molecularly targeted drugs, 117m TOR, 371Multidrug resistance, 215Mutations, 41 Nasopharyngeal carcinoma (NPC), 145Newly diagnosed, 117NF-κB signal pathway, 405Non-small lung cancer, 81Non-small cell lung cancer (NSCLC), 9, 181, 197, 263, 271, 295, 345Non-small cell lung cancer cells (NSCLCs), 1 gene, 41PFTK1, 137, 181PI3K/Akt pathway, 429, 437, 513PI3K/Akt signaling, 305PI3K/Akt signaling pathway, 215, 361PI3K/Akt/m TOR pathway, 287, 489Platinum-based chemotherapy, 129Prognostic factors, 73Progression-free survival, 129Proliferation, 153, 171, 197, 337, 353, 361, 371, 381, 391, 455, 489Prostate cancer, 305Prostate cancer-associated transcription 6 (PCAT6), 161Pyruvate kinase isozyme type M2 (PKM2), 463Quality of life, 523Radiosensitization, 1Radiotherapy and temozolomide, 117Rap1b, 287Relapse, 73Renal cancer, 65Renal cell cancer, 327Renal cell carcinoma (RCC), 479Resistance, 81, 295REV7, 315Ribosomal protein (RP)–p53 pathway, 9Ritonavir, 327SAM- and SH3-domain containing 1 (SASH1), 17, 25SB431542, 1SCC25 cells, 399Second-line treatment, 129Signaling pathway, 463Simvastatin, 523SLC39A5 (ZIP5), 205SMMC-7721, 239Sparc/osteonectin, cwcv, and kazal-like domains proteoglycan (testican) 1 (SPOCK1), 437Src, 225STAT3, 371T cells, 189TIPE2, 255Tongue squamous cell carcinoma (TSCC), 399TRAIL, 497Transforming growth factor-β1 (TGF-β1), 1, 33, 315Transforming growth factor-β-induced 2 (TGFI2), 353Transforming growth factor-β receptor 2 (TGFBR2), 415Treatment, 117Triple-negative breast cancer (TNBC), 233Tumor necrosis factor-α (TNF-α), 233Tumor necrosis factor-α (TNF-α)-induced protein 8-like 2 (TNFAIP8L2, TIPE2), 305Tumor suppressor, 99Tumorigenesis, 263Ubiquitin-conjugating enzyme E2T (UBE2T), 361Ubiquitin-specific peptidase 17 (USP17), 263Ultraconserved element 338 (uc.338), 337Upregulated gene 11 (URG11), 197Whole-brain radiation therapy (WBRT), 523Wnt pathway, 109Wnt/β-catenin pathway, 271Wnt/β-catenin signaling, 479Wnt/β-catenin signaling pathway, 197Xenograft, 205Zinc, 205Agha, M., 137Bai, Mingzhu, 267Bai, Yun, 205Boyiadzis, M., 137Cao, Chu-yu, 79Chaudhri, S., 291Chen, Gang, 119Chen, Min, 61Chen, Xiangming, 197Choghaei, E., 69Copur, M. H., 67Lee, S.-J., 93Lee, T.-H., 391Lee, W.-S., 115Li, B., 131Li, D., 141Li, H., 237Li, H., 149Li, H., 171Li, S., 303Li, S., 555Li, X., 323Li, X., 35Li, X., 149Li, Z., 77Li, Z.-H., 125Li, Z., 149Li, Z.-L., 125Liang, J., 225Liang, Y., 149Liao, F., 203Libby, E., 93Lim, D.-H., 381Lin, L., 125Liu, B., 131Liu, H., 171Liu, H., 519Liu, S.-Q., 573Liu, T., 125Liu, W., 35Liu, X.-K., 125Liu, Z., 131Liu, Z., 563Long, Y., 149Loudon, J. R., 287Milione, M., 403Mirzayans, R., 265Misawa, A., 23Mittal, B., 165Miwa, N., 203Mochinaga, S., 111, 511Moghadam, M. J., 349Montazeri, V., 375Moon, A., 297Mori, K., 543Morita, J., 479Mozzetti, S., 13Murray, D., 265Myung, S. I., 471Naito, Y., 543Nakamura, T., 85Nakamura, T., 111Nakano, K., 463Nakano, Y., 511Nakashima, M., 463Nam, D.-H., 381Naoe, M., 479Nation, P. V., 105Shao, Q., 225Sharma, A., 365Sharma, K., 165Sharma, M., 365Shi, K., 77Shichijo, T., 479Shukla, Y., 245Sil, H., 335Simizu, S., 445Singh, M., 245Singh, R., 245Somoza-Martín, J. R., 99Togano, T., 463Tomida, A., 23Tong, G.-Z., 323Tsuboi, S., 85Tyagi, S., 245Uchida, J., 399Uchiyama, K., 543Um, H.-D., 381Ureshino, N., 111Uysal, M., 259von Carlowitz, I., 349Wallace, E., 349Wang, A., 303Wang, B., 349Wang, G., 193Wang, H., 501Wang, J., 501Wang, M., 535Wang, R., 141Wang, T., 171Wang, T., 193Wang, W., 141Wang, Y., 501Wang, Y., 501Watanabe, M., 463Watanabe, T., 23, 463Xiao, H., 35Xie, Q., 555Xie, X., 131Xing, F., 501Xioa, M.-C., 535Xu, C., 77Xu, M.-K., 125Xun, P., 171Yagi, N., 543Yakabe, T., 511Yamaguchi, A., 527Yamamoto, H., 85Yamaya, K., 85Yan, W., 563Yang, B.-F., 323Yang, H.-A., 535Yang, H.-Y., 391Yang, J., 519Yang, L., 35Yang, U., 391Yang, W.-F., 125Yang, Y., 77Yang, Y., 225Yang, Y., 501Yang, Y.-J., 323Yang, Z. P., 269Clézardin, P., 173 (357*)Costarelli, L, 409Cui, L., 305Dan, L., 593Daniels, B. H., 221Giacconi, R., 409Goi, T., 541Gong, Y., 437Grossmann, M. J., 287Hosono, T., 575Hosono-Fukao, T., 575Hsieh, C.-Y., 279Hu, H., 561Hu, Z., 305Huang, C.-Y., 279Huang, F., 1Huang, G., 31Huang, H., 437Huang, H.-Z., 377Huang, K., 229Huang, L., 203Huang, X.-Y., 503Iitsuka, Y., 575Iwamoto, S., 493Jai, T., 73Jain, M., 41Jansen, J. It is the responsibility of the corresponding author to ensure that this occurs. Mercer American Continent: Edward Chu University of Pittsburgh Cancer Institute, USAEmail: This e-mail address is being protected from spambots. Workman, CRC Center for Cancer Therapeutics, UKAsia and Pacific Rim: Kazuo , RIKEN, Japan E. S., 1Cui, Ya Jie, 275Du, Xilin, 43Du, Yanwei, 229Eren, M., 1Falahati, M., 61Fan, Li-Qiao, 129Fan, Yaohua, 219Fang, Weiyi, 61Fang, Yong, 219Farah, R., 137Feng, Youji, 267Gao, Ji, 321Gao, Jianjun, 43Gauchan, D., 1Ge, Honglei, 171Ghosh-Laskar, S., 183Gong, Weihong, 283Gu, Hongli, 61Gu, Yuanting, 165Guo, Baofeng, 229Guo, Ensong, 119Guo, Meng, 291Guo, Yihang, 303Hasanpour, M., 69Hashemi, Z. A., 55, 407Lu, S., 225Lu, S., 519Luo, J., 563Lv, Z., 131Lyon, M. A., 165Malki, A., 275Mariani, M., 13Matsumoto, T., 543Mc Ewan, A. N., 287Nishino, K., 399 Noh, D.-Y., 297Noshiro, H., 511Ogawa, Y., 479Ohyama, C., 85Okahashi, T., 511Okamoto, A., 85Okyuama, T., 399Osada, H., 445Park, B.-J., 391Park, C.-H., 115Park, S.-J., 115Park, S.-Y., 455Park, Y.-L., 115Pérez-Sayáns, M., 45Pillai, R., 99Po, H. K., 471Riauka, T., 287Saitoh, H., 85Saitoh, Y., 203Sakamoto, N., 543Sato, A., 217Sato, T., 85Satyam, A., 365Sayar, H., 93Scambia, G., 13Sen, T., 335Şener, G., 259Seol, H. L., 487Yi, E.-Y., 455Yin, J., 131Yoneyama, T., 85Yoo, H. J., 381Yosikawa, T., 543Youssef, A., 275Yu, M., 149Yu, Y., 141Yun, H.-Y., 237Zargar, S. E., 269Gu, P., 133Guan, H., 117Guan, X.-X., 503Guillet, B., 173Gunduz, E., 509Gunduz, M., 509Guo, J., 519Habler, L., 537Haghighi, M.

In order to cover the costs of the journal, authors are expected to pay a publication fee. The Open Access fee entitles the corresponding author to a free PDF file of the final version in addition to a hard copy of the journal issue. K., 203Lei, W., 73Li, F.-Y., 503Li, J., 359Li, T., 305Li, Y., 561Li, Z., 1Liao, Z.-W., 503Lin, M.-C., 279Liu, A., 519Liu, Y., 519Long, F., 401López-Cortés, A., 395Mahmoudi, T., 57Mainetti, L. J., 315Morita, J., 153, 493Müller, A., 387Muñoz, M. Color Option: Your article may contain figures that should be printed in color. E., 601Malavolta, M., 409Mangoldt, D., 95Matar, P., 601Matoušek, J., 163Matoušek, J., 163Mc Clelland, M., 401Menaa, F., 173Mittal, B., 41, 329Mittal, R. K., 269Mladosievicova, B., 607Mocchegiani, E., 409Mohebbi, S. J., 395Nagai, N., 509Nagatsuka, H., 509Nagini, S., 193Naidu, R., 65Naoe, M., 153, 493Narasimhan, M. V., 349Ninomiya, Y., 529Ogawa, Y., 153, 493Ohmori, T., 337Ohnishi, T., 337Okuda, K., 337Olevson, Y., 537Orlando, F., 409Ostad, S. Financial support and conflicts of interest for all authors must be declared. You need Java Script enabled to view it Asia and Pacific Rim: Kazuo Umezawa Aichi Medical University School of Medicine, Japan Email: This e-mail address is being protected from spambots. S., 69Hou, Jing-Zhou, 137Hu, Junbo, 119Hu, Liang, 109Huang, Jing, 61Huang, Yujie, 61Jambhekar, N., 183Jamison, C., 1Ji, Young Rae, 89Jia, Huijie, 321Jia, Lijun, 249Jia, Xiaolong, 321Jin, Wei, 219Joshi, A., 183Khamisipour, G., 69Kim, Hyeng-Soo, 89Kim, Myoung Ok, 89Kim, Sung-Hyun, 89Kraiklang, R., 21Lan, Qiuping, 219Lee, Bo Ram, 89Li, Chenglin, 283Li, Dongming, 61Li, Fangguo, 155Li, Juan, 205Li, Kezhen, 119Li, Liang, 79Li, Lin, 165Li, Ning, 257Li, Pihong, 29Li, Qian, 79Li, Wen, 61Li, Xiangyong, 109Li, Xiaorong, 303Li, Xidong, 171Li, Yan, 43Li, Yang, 229Li, Yiming, 249Li, Yong, 129Lin, Bihua, 109Lin, Changwei, 303Lin, Yan, 137Liu, Bing-tong, 311Liu, Chao, 311Liu, Fei, 109Liu, Gao, 99Liu, Ming, 257Liu, Mingxing, 13Liu, Rong-rong, 311Liu, Wei, 7Liu, Wenzhi, 197Liu, Xin, 109Liu, Zhewen, 229Lou, Fang, 219Lou, Haizhou, 219Lu, Hao, 119Lu, Meng, 267Lu, Pengwei, 165Lu, Yandong, 155Lv, Huiqing, 283Lv, Ya-feng, 79Lyu, Quanchao, 61 Ma, Ding, 119Ma, Hongbing, 249Ma, Yeufan, 109Mahajan, A., 183Marks, S., 137Mehta, S. R., 381Postema, E., 287Preet, R., 311Prislei, S., 13Procopio, G., 403Pusceddu, S., 403Qin, D., 193Qin, M.-B., 573Qing, C., 149Rabinowitz, I., 93Rajappa, M., 365Raspaglio, G., 13Ren, L., 391Rey, J. A., 165Zarghami, N., 375Zhang, H., 501Zhang, J., 35Zhang, W., 555Zhang, X., 149Zhang, Y., 149Zhang, Z. J., 365Cabera, A., 395Camci, C., 583Cao, Y., 117Cao, Z., 305Castro, B., 395Chadha, V. J., 25Chang, K.-T., 259Chaudhry, P., 549Chen, J., 437Chen, K., 561Chen, L., 503Chen, W., 519Chen, Y.-L., 279Cheng, W.-F., 279Choi, S.-H., 401Choi, Y. Further information on this can be obtained from the International Committee for Medical Journal Editors ( You need Java Script enabled to view it European Continent: Enrico Mini University of Florence, Italy Email: This e-mail address is being protected from spambots. Zhang, University of Pittsburgh, USAEuropean Continent: Enrico Mini, Co-Editor-in-Chief A. A., 183Meng, Fei, 7Meng, Hui, 205Meng, Li, 119Meng, Yan, 229Meng, Zhi-jian, 35Miao, Yi, 267Mossahebi-Mohammadi, M., 69Naeimi, B., 69Nakti, D., 183Nelson, D., 1Noronha, V., 183Norvell, M., 1Okada, S., 21Pan, Hongming, 219Pantanowitz, L., 137Park, Hum Dai, 89Park, Si Jun, 89Patil, P. M., 183Prabhash, K., 183Purandare, N., 183Qi, Lan, 267Qian, Ying, 137Qin, Ye, 79Qin, Yun, 13Qiu, Xinguang, 165Ramaekers, R., 1Raptis, A., 137Rea, D., 291Ren, Hongtao, 249Roth, C. L., 311Bai, Qing-Ling, 159Boyiadzis, M., 85, 117Cai, Qiqing, 21Cao, Hui-qin, 259Cao, Neng, 129Chatta, G., 311Chen, Guang, 13Chen, Hu, 185Chen, Kai, 67Chen, Yawei, 283Cheng, Guang-hui, 219Cheng, Xiaolin, 283Clark, D., 321Copur, M. E., 311Dai, Xiaoyu, 39Ding, Fei, 85Dong, Mingjun, 39Dong, You-Yuan, 167Duggal, S., 85Eo, Seong-Hui, 147Fan, Cong, 193Fan, Qiong-Ying, 247Fang, Shuo, 185Farah, R., 85Feng, Jun, 67Fenton, M., 117Ferrone, S., 117Fu, Shengling, 13Gao, Bu-Lang, 247Gao, Songtao, 21Gauchan, D., 321Gillespie-Twardy, A. B., 311Gu, Xingang, 267Guo, Jie, 225Guo, Qing, 247Guo, Wei-Chun, 185 Handa, N., 325Hao, Meijun, 203Hao, Ming, 203He, Sisi, 139Horie, K., 105Hou, Jing-Zhou, 85Hu, Caixia, 203Hu, Chang-Wei, 159Hu, Li, 57Hu, Xiongbing, 203Hu, Yingbin, 235Hu, Yong-quan, 293Im, A., 85Ji, Peng, 185Jiang, Bin, 29Jiang, Jiemin, 267Jiang, Zhi-Chao, 57Jin, Hong, 167Ju, Yuanrong, 123Kang, Xiangdong, 267Kim, Ju-Hee, 147Kim, Song-Ja, 147Kong, Fei-Fei, 29Kong, Feng, 219Kong, Qianqian, 267Korty, T., 1 Lei, Lei, 301Li, Cong, 203Li, Da-Peng, 67Li, Hong-Xing, 57Li, Jia, 203Li, Kai-lin, 219Li, Keqiang, 39Li, Li, 193Li, Li, 203Li, Li-Li, 57Li, Wei, 67Li, Wen-Ling, 159Li, Ye, 75Li, Yun-feng, 225Li, Zheng, 333, 339Liang, Lingxia, 283Liao, Haiqiu, 235Liao, Yongde, 13Lin, Feng, 75Lin, Qingfeng, 75Lin, Yan, 85Lin, Zhi-Guo, 57Liu, Feng, 29Liu, Guo-Chao, 247Liu, Heng-chao, 293Liu, Huawei, 203Liu, Hui, 259Liu, Jiayu, 47Liu, Lele, 47Liu, Liang, 235Liu, Lili, 47Liu, Ru-yan, 93Liu, Shaoping, 75Liu, Xiao-dong, 225Liu, Xiao-Fang, 177Liu, Yu-hong, 259Liu, Zhaoguo, 13Liu, Zhong-shan, 225Long, Jiang, 203Lou, Ge, 167Luan, Yun, 219Lv, Yan-Ming, 159Ma, Fang, 293Ma, Jun, 105Ma, Ningqiang, 47Mao, Weidong, 75Meadows, C., 1Mei, Hong-Jun, 185Men, Xuelin, 123Minakata, K., 325Morré, D. M., 1 Nan, Kejun, 301Ni, Juan, 129Norvell, M., 321Osawa, H., 325Pan, Chunying, 267Pan, Shaojun, 293Pang, Hailin, 47Passero, V., 311Puweizhong, Huang, 275Qi, Pengwei, 283Qian, Wenjun, 75Qiu, Ling, 225Ramaekers, R., 321Raptis, A., 85Redner, R. N., 67Kim, W., 381Kim, Y., 381Kim, Y.-J., 455Kimura, S., 111, 511Kitahara, K., 511Koga, S., 511Koh, Y.-S., 115Koie, T., 85Koike, S., 23Kokura, S., 543Kong, C.-Z., 125Koslowsky, I., 265Koul, A., 179Kumagai, T., 399Kundu, C. G., 487Zhang, Z., 141Zhang, Z., 303Zhao, M., 323Zhao, P., 225Zheng, J., 35Zheng, X., 555-Adrenergic receptor, 45Akt, 245Aminoglycosides, 55Angiogenesis, 303, 455Antioxidant enzymes, 259, 365Antisense oligonucleotide, 265AP-1, 115Apoptosis, 35, 45, 77, 245, 303, 323, 391, 535Arsenic trioxide, 149Ataluren, 55Autophagy, 303, 179Bacitracin, 445Bad, 67Barrett's esophagus, 141Basic fibroblast growth factor (b FGF), 455Bax, 275Bcl-2, 149Benign prostatic hyperplasia (BHP), 225β-Adrenergic agonist, 45β-Adrenergic antagonist, 45β-Adrenergic receptors, 45β-Adrenergic receptor, 45β-Catenin, 237β-Glucan, 259Bilateral breast cancer, 171Bisphosphonate, 287Bladder cancer, 125, 535Bladder tumor, 85Bone metastases, 287Breast cancer, 275, 287, 375, 519Burkitt lymphoma, 149Cancer, 543Cancer of posterior one third of the tongue, 365Cancer stem cell (CSC), 23, 555Canine models, 225Cardiac pre-/postconditioning, 407β-Catenin, 237CD30, 463Celecoxib, 131Cell cycle, 349Cell growth, 527Cell invasion, 297Cell line A549, 323Cell proliferation, 535Cervical cancer, 245Checkpoint kinase 1 (Chk1), 349Checkpoint, 349Chemopotentiation, 349Chemoresistance, 13, 23, 471Chemotaxis, 45Chemotherapy, 399Chemotherapy/radiotherapy resistance, 407Circulating tumor cells, 487Cisplatin, 471Clinicopathology, 141c-Met tyrosine kinase, 131Coenzyme Q10 (Co Q10), 455Colon, 1Colon cancer, 527Colorectal cancer, 311, 573Colorectal neoplasms, 487Combination therapy, 311Combretastatin A4 phosphate (CA4P), 303Compassionate use, 403Concomitant chemoradiation, 365Conjugated dienes, 365CXC chemokine receptor 4 (CXCR4), 555Cyclin D1 (CCND1), 519Cyclin-dependent kinase, 349Cyclooxygenase-2, 245, 111Diagnosis, 105Direct sequencing, 111DNA damage, 311DNA damage checkpoint, 381DNA fragmentation, 203Dormant cancer, 407Dose intensity, 511Doxorubicin, 131Encephalopathy, 399Epidermal growth factor receptor (EGFR) inhibitor, 471(−)-Epigallocatechin 3-gallate (EGCG), 391Epigenetics, 105ERK, 275, 455ERK1/2, 463, 573Erlotinib, 399Esophageal adenocarcinoma, 141Esophageal and gastric cancer, 165Everolimus, 403Experimental carcinogenesis, 1Fibronectin, 335Fluorine-18, 2655-Fluorouracil, 311Fullerene [C, 297G870A polymorphism, 519Gemcitabine, 287Gene expression, 375Glioma, 555β-Glucan, 259Glutathione, 365HCT116, 265Hemaglutinin, 323Hepatocellular carcinoma, 115, 131Hepatocyte growth factor (HGF), 67, 93Hepatocyte growth factor receptor, 131Hepatoma-derived growth factor (HDGF), 67Heterodimerization (HD) domain, 99Hibernating myocardium, 407Histone deacetylase (HDAC), 217Hodgkin lymphoma, 463IκBα, 463i ASPP, 125Immunohistochemistry, 141India, 99Indole-3-carbinol, 237Inhibitor, 445Insulin-like growth factor-1 receptor (IGF-1R), 35Integrin, 335Interferon-α (IFN-α), 479Interferon-γ (INF-γ, 543Interleukin-2 (IL-2), 479Invadopodia, 85Invasiveness, 563Ionizing radiation, 265Irradiation, 203Ischemic myocardium, 407JNK, 275Juniferdin, 445Kashmir Valley, 165KITENIN, 115Lentivirus, 563LIMK1, 501Lipid peroxidation, 259, 365Lung cancer, 471MAPK, 115, 311Mat Ly Lu Dunning prostatic adenocarcinoma, 259Matrix metalloproteinase-2 (MMP-2), 297MCL-1, 149MDA-MB-231, 287MED19, 193Melatonin, 259MET, 93Meta-analysis, 519Metastasis, 67Metastatic brain tumor, 381Metastatic colorectal cancer, 511Metastatic phenotype, 573Metformin, 275Methylation markers, 105MG63, 501Microfluidic analytical techniques, 487Micro RNA (mi RNA), 23Migration, 237, 501MMP-9, 335Modified FOLFOX6 (m FOLFOX6), 511Multidrug resistance, 501Multiple myeloma cell, 391Murine melanoma, 335Mutated (S351A)RIN1, 527Natural killer (NK) cell, 479Neoplasm metastasis, 487Neuroendocrine tumor, 403Newcastle disease virus (NDV), 323NF-κB, 463Nonsense mutations, 55Non-small cell lung cancer, 323Notch-1 receptor, 99Nuclear factor-κB (NF-κB), 245NVP-ADW742, 35Octreotide, 403Orthotopic mouse model, 131Osteosarcoma, 193, 501Ovarian cancer, 13p21, 265, 275p53, 275Peroxiredoxin V (Prdx V), 391Peroxisome proliferation-activated receptor-γ (PPAR-γ), 141Phorbol 12-myristate 13-acetate (PMA), 573Phosphorylated Chk1 (P-Chk1), 381Photodynamic therapy (PDT), 203Phytochemicals, 179PIK3CA, 563 Ins16bp polymorphism, 165Primary cancer, 105Prognosis, 105, 171Programmed cell death, 303Proliferating cell nuclear antigen, 131Proliferation, 125, 193, 563Proline, glutamic acid, serine, threonine-rich (PEST) domain, 99Prostate cancer, 237Prostate-specific antigen (PSA), 225, 375Prosurvival factors, 407Protein disulfide isomerase, 445Protein kinase Cα (PKCα), 77Quenching probe, 111Radioresistance, 381Reactive oxygen species (ROS), 77, 203Regulatory T cells (Tregs), 543Renal cancer, 217Renal cell cancer (RCC), 479Resveratrol, 311Ribosomal read-through, 55RIN1 gene, 527Risk, 519RNA interference, 125, 193RON, 13sh RNA, 535, 563Side population (SP), 23Signaling, 335Single nucleotide polymorphism, 111Skin tumors, 179Sodium selenite, 77Sphingosine kinase 1 (SPHK1), 573Suberoylanilide hydroxamic acid (SAHA), 217Survivin, 149, 535Targeted therapies, 403T-Cell acute lymphoblastic leukemia (T-ALL), 99Tea polyphenols, 245Telomerase, 375Therapeutic response, 365Three-dimensional conformal stereotactic radiation therapy (3D-CRT), 225Thromboembolism, 93Thrombosis, 93Tongue cancer, 563Top BP1, 381Topotecan, 217Transcription factors, 179Transient, 399Treatment and follow-up, 171Treg cell, 479Tumor invasion, 85Tumor suppressor proteins, 55Tyrosine kinase receptor, 13Ultrastructure, 1Unilateral breast cancer, 171Adachi, M., 337Advani, R., 287Albrecht, C.

tang yan hd sex photo in-7tang yan hd sex photo in-78tang yan hd sex photo in-48

Flow cytometric evaluation of double/triple hit lymphoma. Surveillance, Epidemiology, and End Results (SEER) Program Research Data (1973-2011).

One thought on “tang yan hd sex photo in”